γ-Catenin at adherens junctions: Mechanism and biologic implications in hepatocellular cancer after β-Catenin knockdown

Neoplasia (United States)

Volumn 15, Issue 4, 2013, Pages 421-434

  Wickline, Emily Diane ^a   Du, Yu ^a   Stolz, Donna B ^a   Kahn, Michael ^b   Monga, Satdarshan P S ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; PLAKOGLOBIN; SERINE; THREONINE; UVOMORULIN; WNT PROTEIN;

ANIMAL TISSUE; ARTICLE; CELL ADHESION; CELL JUNCTION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DESMOSOME; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IMMUNOPRECIPITATION; KNOCKOUT MOUSE; LIVER CELL CARCINOMA; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING; WOUND HEALING;

EID: 84875671118     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.122098     Document Type: Article

References (71)

1. El-Serag HB (2004). Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127, S27-S34.
2. Parkin DM, Bray F, Ferlay J, and Pisani P (2005). Global cancer statistics, 2002. CA Cancer J Clin 55, 74-108.
3. Waly Raphael S, Yangde Z, and Yuxiang C (2012). Hepatocellular carcinoma: focus on different aspects of management. ISRN Oncol 2012, 421673.
4. Kondo Y, Kanai Y, Sakamoto M, Genda T, Mizokami M, Ueda R, and Hirohashi S (1999). Beta-catenin accumulation and mutation of exon 3 of the beta-catenin gene in hepatocellular carcinoma. Jpn J Cancer Res 90, 1301-1309.
5. Legoix P, Bluteau O, Bayer J, Perret C, Balabaud C, Belghiti J, Franco D, Thomas G, Laurent-Puig P, and Zucman-Rossi J (1999). Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity. Oncogene 18, 4044-4046.
6. Wong CM, Fan ST, and Ng IO (2001). Beta-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer 92, 136-145.
7. de La Coste A, Romagnolo B, Billuart P, Renard CA, Buendia MA, Soubrane O, Fabre M, Chelly J, Beldjord C, Kahn A, et al. (1998). Somatic mutations of the β-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 95, 8847-8851.
8. Emami KH, Nguyen C, Ma H, Kim DH, Jeong KW, Eguchi M, Moon RT, Teo JL, Kim HY, Moon SH, et al. (2004). A small molecule inhibitor of β-catenin/CREB-binding protein transcription [corrected]. Proc Natl Acad Sci USA 101, 12682-12687.
9. Stock P, Monga D, Tan X, Micsenyi A, Loizos N, and Monga SP (2007). Plateletderived growth factor receptor-α: a novel therapeutic target in human hepatocellular cancer. Mol Cancer Ther 6, 1932-1941.
10. Behari J, Zeng G, Otruba W, Thompson MD, Muller P, Micsenyi A, Sekhon SS, Leoni L, and Monga SP (2007). R-Etodolac decreases β-catenin levels along with survival and proliferation of hepatoma cells. J Hepatol 46, 849-857.
11. Thompson MD, Dar MJ, and Monga SP (2011). Pegylated interferon alpha targets Wnt signaling by inducing nuclear export of β-catenin. J Hepatol 54, 506-512.
12. Clevers H and Nusse R (2012). Wnt/β-catenin signaling and disease. Cell 149, 1192-1205.
13. Nejak-Bowen KN and Monga SP (2011). Beta-catenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad. Semin Cancer Biol 21, 44-58.
14. Tan X, Behari J, Cieply B, Michalopoulos GK, and Monga SP (2006). Conditional deletion of beta-catenin reveals its role in liver growth and regeneration. Gastroenterology 131, 1561-1572.
15. Choi HJ, Gross JC, Pokutta S, and Weis WI (2009). Interactions of plakoglobin and β-catenin with desmosomal cadherins: basis of selective exclusion of α-and β-catenin from desmosomes. J Biol Chem 284, 31776-31788.
16. Maeda O, Usami N, Kondo M, Takahashi M, Goto H, Shimokata K, Kusugami K, and Sekido Y (2004). Plakoglobin (γ-catenin) has TCF/LEF family-dependent transcriptional activity in β-catenin-deficient cell line. Oncogene 23, 964-972.
17. Kim YM, Ma H, Oehler VG, Gang EJ, Nguyen C, Masiello D, Liu H, Zhao Y, Radich J, and Kahn M (2011). The gamma catenin/CBP complex maintains survivin transcription in β-catenin deficient/depleted cancer cells. Curr Cancer Drug Targets 11, 213-225.
18. Anderson JM (1996). Leaky junctions and cholestasis: a tight correlation. Gastroenterology 110, 1662-1665.
19. Sakisaka S, Kawaguchi T, Taniguchi E, Hanada S, Sasatomi K, Koga H, Harada M, Kimura R, Sata M, Sawada N, et al. (2001). Alterations in tight junctions differ between primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology 33, 1460-1468.
20. Cao Y, Chang H, Li L, Cheng RC, and Fan XN (2007). Alteration of adhesion molecule expression and cellular polarity in hepatocellular carcinoma. Histopathology 51, 528-538.
21. Zhai B, Yan HX, Liu SQ, Chen L, Wu MC, and Wang HY (2008). Reduced expression of E-cadherin/catenin complex in hepatocellular carcinomas. World J Gastroenterol 14, 5665-5673.
22. Zhang XF, Tan X, Zeng G, Misse A, Singh S, Kim Y, Klaunig JE, and Monga SP (2010). Conditional β-catenin loss in mice promotes chemical hepatocarcinogenesis: role of oxidative stress and platelet-derived growth factor receptor α/phosphoinositide 3-kinase signaling. Hepatology 52, 954-965.
23. Rubiolo JA, Lopez-Alonso H, Vega FV, Vieytes MR, and Botana LM (2011). Okadaic acid and dinophysis toxin 2 have differential toxicological effects in hepatic cell lines inducing cell cycle arrest, at G0/G1 or G2/M with aberrant mitosis depending on the cell line. Arch Toxicol 85, 1541-1550.
24. Gesty-Palmer D, Chen M, Reiter E, Ahn S, Nelson CD, Wang S, Eckhardt AE, Cowan CL, Spurney RF, Luttrell LM, et al. (2006). Distinct β-arrestin-and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. J Biol Chem 281, 10856-10864.
25. Hirooka K, Kourennyi DE, and Barnes S (2000). Calcium channel activation facilitated by nitric oxide in retinal ganglion cells. J Neurophysiol 83, 198-206.
26. Yu P, Han W, Villar VA, Li H, Arnaldo FB, Concepcion GP, Felder RA, Quinn MT, and Jose PA (2011). Dopamine D1 receptor-mediated inhibition of NADPHoxidase activity in human kidney cells occurs via protein kinase A-protein kinase C cross talk. Free Radic Biol Med 50, 832-840.
27. Breitwieser GE and Gama L (2001). Calcium-sensing receptor activation induces intracellular calcium oscillations. Am J Physiol Cell Physiol 280, C1412-C1421.
28. Citi S (1992). Protein kinase inhibitors prevent junction dissociation induced by low extracellular calcium in MDCK epithelial cells. J Cell Biol 117, 169-178.
29. Kelps KA, Turchan-Cholewo J, Hascup ER, Taylor TL, Gash DM, Gerhardt GA, and Bradley LH (2011). Evaluation of the physical and in vitro protective activity of three synthetic peptides derived from the pro-and mature GDNF sequence. Neuropeptides 45, 213-218.
30. Simcha I, Shtutman M, Salomon D, Zhurinsky J, Sadot E, Geiger B, and Ben-Ze'ev A (1998). Differential nuclear translocation and transactivation potential of β-catenin and plakoglobin. J Cell Biol 141, 1433-1448.
31. Wickline ED, Awuah PK, Behari J, Ross M, Stolz DB, and Monga SP (2011). Hepatocyte γ-catenin compensates for conditionally deleted β-catenin at adherens junctions. J Hepatol 55, 1256-1262.
32. Monga SP, Mars WM, Pediaditakis P, Bell A, Mule K, Bowen WC, Wang X, Zarnegar R, and Michalopoulos GK (2002). Hepatocyte growth factor induces Wnt-independent nuclear translocation of β-catenin after Met-β-catenin dissociation in hepatocytes. Cancer Res 62, 2064-2071.
33. Wack KE, Ross MA, Zegarra V, Sysko LR, Watkins SC, and Stolz DB (2001). Sinusoidal ultrastructure evaluated during the revascularization of regenerating rat liver. Hepatology 33, 363-378.
34. Behari J, Yeh TH, Krauland L, Otruba W, Cieply B, Hauth B, Apte U, Wu T, Evans R, and Monga SP (2010). Liver-specific β-catenin knockout mice exhibit defective bile acid and cholesterol homeostasis and increased susceptibility to diet-induced steatohepatitis. Am J Pathol 176, 744-753.
35. Awuah PK, Rhieu BH, Singh S, Misse A, and Monga SP (2012). β-Catenin loss in hepatocytes promotes hepatocellular cancer after diethylnitrosamine and phenobarbital administration to mice. PLoS One 7, e39771.
36. Zou L, Jaramillo M, Whaley D, Wells A, Panchapakesa V, Das T, and Roy P (2007). Profilin-1 is a negative regulator of mammary carcinoma aggressiveness. Br J Cancer 97, 1361-1371.
37. Fukunaga Y, Liu H, Shimizu M, Komiya S, Kawasuji M, and Nagafuchi A (2005). Defining the roles of β-catenin and plakoglobin in cell-cell adhesion: isolation of β-catenin/plakoglobin-deficient F9 cells. Cell Struct Funct 30, 25-34.
38. Sekine S, Ogawa R, and Kanai Y (2011). Hepatomas with activating Ctnnb1 mutations in 'Ctnnb1-deficient' livers: a tricky aspect of a conditional knockout mouse model. Carcinogenesis 32, 622-628.
39. Thompson MD, Wickline ED, Bowen WB, Lu A, Singh S, Misse A, and Monga SP (2011). Spontaneous repopulation of β-catenin null livers with β-catenin-positive hepatocytes after chronic murine liver injury. Hepatology 54, 1333-1343.
40. Miravet S, Piedra J, Castano J, Raurell I, Franci C, Dunach M, and Garcia de Herreros A (2003). Tyrosine phosphorylation of plakoglobin causes contrary effects on its association with desmosomes and adherens junction components and modulates β-catenin-mediated transcription. Mol Cell Biol 23, 7391-7402.
41. Pasdar M, Li Z, and Chlumecky V (1995). Plakoglobin: kinetics of synthesis, phosphorylation, stability, and interactions with desmoglein and E-cadherin. Cell Motil Cytoskeleton 32, 258-272.
42. Sacco PA, McGranahan TM, Wheelock MJ, and Johnson KR (1995). Identification of plakoglobin domains required for association with N-cadherin and α-catenin. J Biol Chem 270, 20201-20206.
43. Troyanovsky R, Chitaev N, and Troyanovsky S (1996). Cadherin binding sites of plakoglobin: localization, specificity and role in targeting to adhering junctions. J Cell Sci 109, 3069-3078.
44. Wahl J, Sacco P, McGranahan-Sadler T, Sauppe L, Wheelock M, and Johnson K (1996). Plakoglobin domains that define its association with the desmosomal cadherins and the classical cadherins: identification of unique and shared domains. J Cell Sci 109, 1143-1154.
45. Zhou J, Qu J, Yi XP, Graber K, Huber L, Wang X, Gerdes AM, and Li F (2007). Upregulation of γ-catenin compensates for the loss of β-catenin in adult cardiomyocytes. Am J Physiol Heart Circ Physiol 292, H270-H276.
46. Kowalczyk AP, Palka HL, Luu HH, Nilles LA, Anderson JE, Wheelock MJ, and Green KJ (1994). Posttranslational regulation of plakoglobin expression. Influence of the desmosomal cadherins on plakoglobin metabolic stability. J Biol Chem 269, 31214-31223.
47. Vinken M, Papeleu P, Snykers S, De Rop E, Henkens T, Chipman JK, Rogiers V, and Vanhaecke T (2006). Involvement of cell junctions in hepatocyte culture functionality. Crit Rev Toxicol 36, 299-318.
48. Gosavi P, Kundu ST, Khapare N, Sehgal L, Karkhanis MS, and Dalal SN (2011). E-cadherin and plakoglobin recruit plakophilin3 to the cell border to initiate desmosome assembly. Cell Mol Life Sci 68, 1439-1454.
49. Bonne S, van Hengel J, Nollet F, Kools P, and van Roy F (1999). Plakophilin-3, a novel armadillo-like protein present in nuclei and desmosomes of epithelial cells. J Cell Sci 112(pt 14), 2265-2276.
50. Dounay AB and Forsyth CJ (2002). Okadaic acid: the archetypal serine/threonine protein phosphatase inhibitor. Curr Med Chem 9, 1939-1980.
51. Haystead TA, Sim AT, Carling D, Honnor RC, Tsukitani Y, Cohen P, and Hardie DG (1989). Effects of the tumour promoter okadaic acid on intracellular protein phosphorylation and metabolism. Nature 337, 78-81.
52. Chijiwa T, Mishima A, Hagiwara M, Sano M, Hayashi K, Inoue T, Naito K, Toshioka T, and Hidaka H (1990). Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. J Biol Chem 265, 5267-5272.
53. Amanchy R, Periaswamy B, Mathivanan S, Reddy R, Tattikota SG, and Pandey A (2007). A curated compendium of phosphorylation motifs. Nat Biotechnol 25, 285-286.
54. Li D, Liu Y, Maruyama M, Zhu W, Chen H, Zhang W, Reuter S, Lin SF, Haneline LS, Field LJ, et al. (2011). Restrictive loss of plakoglobin in cardiomyocytes leads to arrhythmogenic cardiomyopathy. Hum Mol Genet 20, 4582-4596.
55. Li J, Swope D, Raess N, Cheng L, Muller EJ, and Radice GL (2011). Cardiac tissue-restricted deletion of plakoglobin results in progressive cardiomyopathy and activation of β-catenin signaling. Mol Cell Biol 31, 1134-1144.
56. Dahmani R, Just PA, and Perret C (2011). The Wnt/β-catenin pathway as a therapeutic target in human hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 35, 709-713.
57. Brooke MA, Nitoiu D, and Kelsell DP (2012). Cell-cell connectivity: desmosomes and disease. J Pathol 226, 158-171.
58. Chidgey M and Dawson C (2007). Desmosomes: a role in cancer? Br J Cancer 96, 1783-1787.
59. Swope D, Cheng L, Gao E, Li J, and Radice GL (2012). Loss of cadherinbinding proteins β-catenin and plakoglobin in the heart leads to gap junction remodeling and arrhythmogenesis. Mol Cell Biol 32, 1056-1067.
60. Lewis JE, Wahl JK, Sass KM, Jensen PJ, Johnson KR, and Wheelock MJ (1997). Cross-talk between adherens junctions and desmosomes depends on plakoglobin. J Cell Biol 136, 919-934.
61. Konopka G, Tekiela J, Iverson M, Wells C, and Duncan SA (2007). Junctional adhesion molecule-A is critical for the formation of pseudocanaliculi and modulates E-cadherin expression in hepatic cells. J Biol Chem 282, 28137-28148.
62. Yoshida M, Ohkusa T, Nakashima T, Takanari H, Yano M, Takemura G, Honjo H, Kodama I, Mizukami Y, and Matsuzaki M (2011). Alterations in adhesion junction precede gap junction remodelling during the development of heart failure in cardiomyopathic hamsters. Cardiovasc Res 92, 95-105.
63. Hinck L, Nathke IS, Papkoff J, and Nelson WJ (1994). Dynamics of cadherin/catenin complex formation: novel protein interactions and pathways of complex assembly. J Cell Biol 125, 1327-1340.
64. Pan H, Gao F, Papageorgis P, Abdolmaleky HM, Faller DV, and Thiagalingam S (2007). Aberrant activation of γ-catenin promotes genomic instability and oncogenic effects during tumor progression. Cancer Biol Ther 6, 1638-1643.
65. Huang WS, Wang JP, Wang T, Fang JY, Lan P, and Ma JP (2007). ShRNAmediated gene silencing of β-catenin inhibits growth of human colon cancer cells. World J Gastroenterol 13, 6581-6587.
66. Liyan W, Xun S, and Xiangwei M (2011). Effect of β-catenin siRNA on proliferation and apoptosis of hepatoma cell line SMMC-7721 and HepG-2. Hepatogastroenterology 58, 1757-1764.
67. Zeng G, Apte U, Cieply B, Singh S, and Monga SP (2007). siRNA-mediated β-catenin knockdown in human hepatoma cells results in decreased growth and survival. Neoplasia 9, 951-959.
68. Zhao JH, Luo Y, Jiang YG, He DL, and Wu CT (2011). Knockdown of β-catenin through shRNA cause a reversal of EMT and metastatic phenotypes induced by HIF-1α. Cancer Invest 29, 377-382.
69. Taurin S, Sandbo N, Qin Y, Browning D, and Dulin NO (2006). Phosphorylation of β-catenin by cyclic AMP-dependent protein kinase. J Biol Chem 281, 9971-9976.
70. Piedra J, Martinez D, Castano J, Miravet S, Dunach M, and de Herreros AG (2001). Regulation of β-catenin structure and activity by tyrosine phosphorylation. J Biol Chem 276, 20436-20443.
71. Zeng G, Apte U, Micsenyi A, Bell A, and Monga SP (2006). Tyrosine residues 654 and 670 in β-catenin are crucial in regulation of Met-β-catenin interactions. Exp Cell Res 312, 3620-3630.